Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation
A Multicenter, 6-month, Open-label Safety Study of Lubiprostone in Pediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation
Sponsor: Sucampo AG
This PHASE3 trial investigates Constipation - Functional and is currently completed. Sucampo AG leads this study, which shows 10 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jan 2020 — Jun 2020 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2020 [monthly]
Completed PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Apr 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Apr 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sucampo AG
- Sucampo Pharma Americas, LLC
For direct contact, visit the study record on ClinicalTrials.gov .